HB 543 creates a new section of Kentucky law governing access to individualized investigational drugs, biological products, and devices for patients with life-threatening or severely debilitating illnesses. The bill defines who qualifies as an eligible patient, including requirements that the patient have a serious illness, have considered FDA-approved options, receive a treating physician’s recommendation, and provide written informed consent. It also defines eligible facilities and sets out detailed consent disclosures about risks, likely outcomes, hospice implications, and financial responsibility.
The bill allows manufacturers operating within eligible facilities to make these individualized treatments available to eligible patients, and permits manufacturers to provide them without compensation or to charge the patient for manufacturing costs. It expressly states, however, that manufacturers are not required to make such treatments available. The bill also protects physicians and other providers from professional discipline or state action based solely on recommending access to these treatments, and bars the Commonwealth from blocking access. In addition, it limits liability by preventing private lawsuits against manufacturers and others involved in the patient’s care if they made a good-faith effort to comply and exercised reasonable care.
HB 543 would affect Kentucky’s health care, licensing, insurance, Medicaid, and liability rules by creating a legal pathway for highly individualized experimental therapies, including gene therapies, antisense oligonucleotides, and neoantigen vaccines. It does not require insurers, third-party administrators, Medicaid, or hospitals to pay for or provide these treatments, and it preserves existing coverage rules for routine patient costs in approved cancer clinical trials. It also provides that heirs are not liable for outstanding treatment-related debt if the patient dies.
The available context shows no recorded committee transcript or vote history, so there is no documented floor or committee debate to gauge sentiment directly. Based on the bill’s structure, it appears designed to expand access to experimental, last-resort treatments while also limiting provider and manufacturer exposure, suggesting a generally pro-access and pro-medical-innovation posture. Likely points of contention include patient safety, informed consent, cost and insurance responsibility, whether the state should shield providers and manufacturers from liability, and whether the bill could pressure vulnerable patients toward unproven therapies.
The bill would add a new statutory framework in KRS Chapter 217 for individualized investigational treatments and would affect Kentucky rules governing medical practice, professional discipline, Medicaid/Medicare certification, insurance coverage, and civil liability. It protects licensed providers from discipline for recommending such treatments, bars state interference with access, and limits lawsuits against manufacturers and others involved in care, while also making clear that coverage and payment obligations are not expanded for insurers, Medicaid, or hospitals.
No committee discussion or vote record is provided, so there is no direct evidence of legislative sentiment in the available materials. The bill’s text suggests a supportive stance toward patient access to experimental therapies and physician discretion, paired with cautionary disclosures and liability limits. Overall, the measure appears to be framed as an access-and-autonomy bill rather than a mandate on insurers or providers.
The main points of contention are likely to center on whether the bill appropriately balances access to experimental treatment with patient protection. Supporters may favor giving terminal or severely ill patients more options and shielding doctors from discipline, while critics may worry about unproven therapies, informed consent quality, financial exposure for patients and families, and the liability protections for manufacturers and providers. Insurance and Medicaid noncoverage, hospice implications, and the possibility of patients bearing all costs are also likely to be disputed.